Cancer Research and Treatment

Original Articles

Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma: Eunyeong Yang, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi, Jung Yong Hong, Minsuk Kwon, Nalee Kim; Received September 5, 2025 Accepted February 1, 2026 Published online February 3, 2026; DOI: https://doi.org/10.4143/crt.2025.966 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Immune checkpoint inhibitors (ICIs) have become a standard therapy for metastatic hepatocellular carcinoma (HCC), often as an alternative to tyrosine kinase inhibitors (TKIs). However, safety data combining ICIs with stereotactic ablative radiotherapy (SABR) remain limited. We compared the safety and efficacy of SABR combined with ICIs versus TKIs in patients with extrahepatic metastatic HCC.
Materials and Methods
This single-center retrospective study included patients with HCC who received SABR for extrahepatic metastases combined with either TKIs or ICIs within 30 days of SABR between January 2010 and June 2024. Adverse events (AEs; Common Terminology Criteria for Adverse Events ver. 5.0) and oncologic outcomes were evaluated using logistic regression and Cox models.
Results
Among 103 patients with 128 SABR-treated lesions, 72 patients (90 lesions) received SABR+TKI and 31 patients (38 lesions) received SABR+ICI. Acute AEs occurred only in the SABR+TKI group (8.9%), predominantly grade 1. Grade 3 late AEs were rare, occurring in one case in each group, while late AEs of lower grades were more frequent with SABR+ICI (any-grade: 57.9% vs. 25.6%, p < 0.001; grade ≥ 2: 23.7% vs. 8.9%, p=0.024). Multivariable analysis showed borderline increased risk of grade ≥ 2 late AEs with SABR+ICI (p=0.052). One-year local control, progression-free survival, and overall survival were 76.6%, 35.3%, and 72.3% respectively, with no significant differences between groups.
Conclusion
Metastasis-directed SABR combined with either TKIs or ICIs was generally well tolerated in patients with extrahepatic metastatic HCC, with rare grade 3 late AEs; grade ≥ 2 late AEs were more frequent with SABR plus ICIs, warranting prospective evaluation.

1,162 View
64 Download

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors: Jin Seok Ahn, Jung Yong Hong, Joon Oh Park, Sung Young Lee, SuYeon Kim, Hwi-yeol Yun, Chan-Young Ock, Woochan Hwang, Sung Ho Kim, Heung Tae Kim, Ho Yeong Lim; Received August 4, 2025 Accepted November 3, 2025 Published online November 4, 2025; DOI: https://doi.org/10.4143/crt.2025.820 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Purpose
IMC-002 is a fully human cluster of differentiation 47-targeted immunoglobulin G4 monoclonal antibody, designed to minimize off-target effects. This study (NCT05276310) assessed its safety/tolerability and preliminary anti-tumor activity in patients with advanced solid tumors who were not eligible for or had progressed on standard treatment.
Materials and Methods
We report results from the initial 3+3 design dose-escalation part of a two-part phase 1, open-label, dose-escalation/expansion study. IMC-002 was administered intravenously every 2 weeks at four doses (5, 10, 20, and 30 mg/kg). The primary objective was to assess safety/tolerability, including maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary objectives included pharmacokinetics and clinical activity, including best overall response (BOR), disease control rate (DCR), and clinical benefit rate (CBR).
Results
Twelve patients were included in total, with three per dose level. Most patients (11/12) had stage IV disease; 7/12 had received three prior systemic therapies. No dose-limiting toxicities were observed and MTD was not reached. The most common treatment-related adverse events were rash (9/12), vitreous floaters (8/12), and (hemolytic) anemia (5/12). There was no treatment-related thrombocytopenia, neutropenia, or infection. IMC-002 had dose-proportional pharmacokinetics, achieving steady state levels from cycle 2. BOR was stable disease in six patients (DCR 50.0%). CBR was 33% (four patients maintaining disease control for ≥ 6 months).
Conclusion
IMC-002 demonstrated favorable safety/tolerability at doses of 5-30 mg/kg every 2 weeks. RP2D was defined as 20 mg/kg every 3 weeks. Preliminary anti-tumor activity was observed, with a CBR of 33%.

Citations

Citations to this article as recorded by

The CD47 signaling axis regulates the formation and vulnerability of atherosclerotic plaques: mechanism analysis and targeting strategies
Liyang Bai, Baofeng Xu, Ying Chen, Dan Fu, Lijuan Wang, Di Ma
Frontiers in Immunology.2026;[Epub] CrossRef
Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding
Tae‐Shin Kim, Jae Hyeon Park, Yousun Chung, Dae‐Hyun Ko, Seon Young Kim, Hyungsuk Kim
Transfusion.2026;[Epub] CrossRef

1,995 View
136 Download
2 Crossref

General

Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers: Minkyue Shin, Dae-Ho Choi, Jaeyun Jung, Deok Geun Kim, Minae An, Sung Hee Lim, Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Kyoung-Mee Kim, Jeeyun Lee; Cancer Res Treat. 2025;57(4):932-941. Published online February 21, 2025; DOI: https://doi.org/10.4143/crt.2024.564

Abstract PDF Supplementary Material PubReader ePub: Purpose
The epidermal growth factor receptor (EGFR) is a therapeutic target with confirmed clinical efficacy for several cancer types. We aimed to identify EGFR aberrations and their associations with other genomic alterations in patients with metastatic diseases of various cancers.
Materials and Methods
We used real-world data from the next-generation sequencing (NGS) of 3,286 patients with metastatic cancer at the Samsung Medical Center. We analyzed the distribution of EGFR amplification, mutation, and fusion, as well as their correlations with microsatellite instability (MSI), tumor mutation burden (TMB), and other gene aberrations.
Results
A total of 3,286 patients were tested using NGS of a panel covering 523 cancer-related genes (TSO500, Illumina) as part of clinical practice between October 2019 and October 2022. Patients with lung cancer and gliomas were not included in the analysis. Of the 3,286 patients, 175 (5.3%) had EGFR amplification, 38 (1.2%) had EGFR mutations, and eight (0.2%) had EGFR fusion. All 175 patients with EGFR amplifications had microsatellite-stable tumors, but 102 had co-amplifications in other cancer-related genes, and 78 had mutations with clinical significance (tier I/II). Among the 38 patients with EGFR mutations, three (8%) showed MSI-high status, and 11 (29%) demonstrated high TMB (≥ 10 mutations/Mb). Among eight patients with EGFR fusion, three exhibited possible functionalities of the EGFR gene.
Conclusion
EGFR aberrations, mainly amplification, followed by mutation and fusion, were present in 6.4% of patients with metastatic solid tumors.

4,059 View
136 Download

Genitourinary cancer

Dose-Response Association between Alcohol Consumption and Kidney Cancer Risk Differs According to Glycemic Status: A Nationwide Cohort Study of 9.4 Million Individuals: Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen, Se Hoon Park; Cancer Res Treat. 2025;57(4):1178-1186. Published online January 31, 2025; DOI: https://doi.org/10.4143/crt.2024.996

Abstract PDF Supplementary Material PubReader ePub

Purpose
Previous studies suggested an association between alcohol consumption and reduced kidney cancer risk. Given a potential interaction between alcohol’s insulin-sensitizing effect and hyperglycemia-related insulin resistance, we aimed to assess whether the dose-response association between alcohol intake and kidney cancer risk varies based on glycemic status.
Materials and Methods
This nationwide cohort study analyzed data from 9,492,331 adults who underwent a national health screening program in 2009 and were followed until 2018. Multivariable-adjusted Cox regression models were applied to estimate the adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).
Results
Over a median follow-up period of 8.3 years, 12,381 participants were diagnosed with kidney cancer. A U-shaped relationship between alcohol consumption and kidney cancer risk was observed among individuals with normoglycemia (light-to-moderate: HR, 0.94; 95% CI, 0.89 to 0.99 and heavy: HR, 1.00; 95% CI, 0.91 to 1.09, respectively). In prediabetic individuals, alcohol consumption was not significantly associated with kidney cancer risk. In individuals with diabetes, a dose-dependent increase in kidney cancer risk was noted with higher alcohol consumption (light-to-moderate consumption: HR, 1.12; 95% CI, 1.03 to 1.22; heavy consumption: HR, 1.24; 95% CI, 1.09 to 1.42; p for trend < 0.01).
Conclusion
A modest U-shaped dose-response association between alcohol consumption and kidney cancer risk was observed exclusively in individuals with normoglycemia. Individuals with diabetes demonstrated a dose-dependent increased risk of kidney cancer with higher alcohol consumption. Tailored patient education and personalized risk assessments regarding alcohol consumption and kidney cancer risk should be emphasized over a generalized ‘one-size-fits-all’ approach.

Citations

Citations to this article as recorded by

Alcohol Consumption Trajectories from Early Adulthood to Adulthood and Cancer Risk in Adulthood: A Systematic Review and Meta-analysis
Samira Behboudi-Gandevani, Ingunn Jystad Brustad, Tommy Haugan, Vegar Rangul, Ellen Christin Arntzen, Marianne Sivertsen, Sarah Cook, Razieh Bidhendi-Yarandi
Cancer Epidemiology, Biomarkers & Prevention.2026; 35(6): 824. CrossRef

7,466 View
138 Download
1 Web of Science
1 Crossref

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Hongsik Kim, Byong Chang Jeong, Joohyun Hong, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Wan Song, Hyun Hwan Sung, Jung Yong Hong, Se Hoon Park; Cancer Res Treat. 2023;55(2):636-642. Published online October 6, 2022; DOI: https://doi.org/10.4143/crt.2022.343

Abstract PDF PubReader ePub

Purpose
The activity and safety of neoadjuvant nivolumab plus gemcitabine/cisplatin (N+GC) were tested in patients with muscle-invasive bladder urothelial carcinoma (MIBC).
Materials and Methods
In a prospective phase II trial, patients with cT2-T4a N0 MIBC who were eligible for cisplatin and medically appropriate to undergo radical cystectomy (RC) were enrolled. Treatment with nivolumab 3 mg/kg on days 1 and 15 plus GC (cisplatin 70 mg/m2 on day 1, and gemcitabine 1,000 mg/m2 on days 1, 8, and 15) was repeated every 28 days up to 3 or 4 cycles, depending on the surgery schedules. The primary endpoint was pathologic complete response (pCR, ypT0). Secondary endpoints included pathologic downstaging (≤ ypT1), disease-free survival (DFS), and safety.
Results
Between September 2019 and October 2020, 51 patients were enrolled. Neoadjuvant N+GC was well tolerated. Among 49 patients who completed neoadjuvant N+GC, clinical complete response (cCR) was achieved in 59% of intent-to-treat (ITT) population. RC was performed in 34 (69%) patients. pCR was achieved in 24% (12/49) of ITT population and 35% (12/34) of RC patients. Median DFS was not reached. Over a median follow-up of 24 months, 12 patients experienced disease recurrence and were treated with palliative therapy or surgery. Although 12 patients declined surgery and were treated with concurrent chemoradiotherapy, DFS was longer in patients with cCR after neoadjuvant therapy than those without. Preoperative programmed death-ligand 1 (PD-L1) did not correlate with pCR or pathologic downstaging rates.
Conclusion
Neoadjuvant N+GC was feasible and provided meaningful pathologic responses in patients with MIBC, regardless of baseline PD-L1 expression (ONO-4538-X41; CRIS.nih.go.kr, KCT0003804).

Citations

Citations to this article as recorded by

Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing
Wei Ning, Pengkang Chang, Ji Zheng, Wei Chen
Frontiers in Immunology.2026;[Epub] CrossRef
Advances in the management of localized bladder cancers
Marie-Pier St-Laurent, Jussi Nikkola, Eisuke Tomiyama, Peter C. Black
Nature Reviews Clinical Oncology.2026; 23(3): 158. CrossRef
Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis
Ana Luíza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Luana Diniz Guerra Braz, Maria Victória Ferreira Piccoli, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes
Immunotherapy.2026; 18(2): 139. CrossRef
Celastrol inhibits the immune escape and proliferation of triple – negative breast cancer (TNBC) through the LKB1 – AMPK – PD-L1/MYC signaling pathway
Mengna Shi, Yujie Li, Wanyu Jin, Yang Xiong
International Immunopharmacology.2026; 179: 116546. CrossRef
Visualizing eligibility gaps between muscle-invasive bladder cancer trials and real-world patients
Takaki Ichiyama, Takuma Narita, Yuya Sekine, Masanao Shinohara, Yohei Kawashima, Mizuki Kobayashi, Kazuyuki Numakura, Jotaro Mikami, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Satoshi Sato, Tomonori Habuchi, Chikara Ohyama, Shingo Hat
Japanese Journal of Clinical Oncology.2026;[Epub] CrossRef
Choosing neoadjuvant therapy for muscle-invasive bladder cancer based on efficacy-safety trade-off: a network meta-analysis
Zilin Zhao, Xinyu Liu, Qikai Zhong, Lin Liu, Runze Pan, Junzhi Chen, Xinlei Wang, Xing Liu, Jiangshang Bao, Yufeng Sun, Conghui Han, Zhenduo Shi, Qing Liang
Frontiers in Oncology.2026;[Epub] CrossRef
Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis
Shugo Yajima, Soichiro Yoshida, Naoki Imasato, Wei Chen, Hiroshi Fukushima, Hajime Tanaka, Hitoshi Masuda, Yasuhisa Fujii
Urologic Oncology: Seminars and Original Investigations.2026; 44(9): 422. CrossRef
Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela Oprea‐Lager, Paramananthan Mariappan, Francesco Sanguedolce, Antoine G. van der Heijden, Laura S. Mertens
BJU International.2026;[Epub] CrossRef
Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma Using Amide Proton Transfer-Weighted MRI
Lingmin Kong, Bei Weng, Qian Cai, Ling Ma, Wenxin Cao, Yanling Chen, Long Qian, Yan Guo, Junxing Chen, Huanjun Wang
Academic Radiology.2025; 32(4): 2090. CrossRef
Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma
Joaquim Bellmunt, Brian M. Russell, Bernadett Szabados, Begoña P. Valderrama, Rosa Nadal
American Society of Clinical Oncology Educational Book.2025;[Epub] CrossRef
Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis
Hao Zhang
American Journal of Translational Research.2025; 17(1): 125. CrossRef
Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period
Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, Tao Xu
Annals of Surgical Oncology.2025; 32(8): 6141. CrossRef
The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer
Joseph Kattan, Clarisse Kattan, Fouad Aoun, Elie Nemr
Frontiers in Oncology.2025;[Epub] CrossRef
Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update
Ilias Giannakodimos, Afroditi Ziogou, Alexios Giannakodimos, Konstantinos Tzelepis, Zisis Kratiras, Evangelos Fragkiadis, Ioannis Zachos, Vasileios Tzortzis, Michael Chrisofos, Nikolaos Charalampakis
Immunotherapy.2025; 17(6): 447. CrossRef
Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors
Xinya Wang, Qin Zhou, Xuyan Zhang, Han Hu, Binlei Liu, Yang Wang
Frontiers in Immunology.2025;[Epub] CrossRef
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates
Takafumi Yanagisawa, Akihiro Matsukawa, Jeremy Yuen-Chun Teoh, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Paweł Rajwa, Fahad Quhal, Benjamin Pradere, Marco Moschini, Shahrokh F. Shariat, Jun Miki, Takahiro Kimura
Bladder Cancer.2025;[Epub] CrossRef
Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis
Akihiro Matsukawa, Angelo Cormio, Marcin Miszczyk, Mehdi Kardoust Parizi, Tamás Fazekas, Ichiro Tsuboi, Stefano Mancon, Robert J. Schulz, Giulio Litterio, Ekaterina Laukhtina, Paweł Rajwa, Thomas Seisen, Keiichiro Mori, Francesca Sanguedolce, Andrea Bened
European Urology Oncology.2025; 8(6): 1673. CrossRef
Novel neoadjuvant therapies for muscle‐invasive bladder cancer: Systematic review and meta‐analysis
Shugo Yajima, Naoki Imasato, Hitoshi Masuda
BJUI Compass.2025;[Epub] CrossRef
Optimizing enfortumab vedotin plus pembrolizumab therapy
Elias Antoine Karam, Yaghi César Céline, Gilles Prince, Fouad Attieh, Hampig Raphael Kourie, Joseph Kattan, Elie Nemer
Oncotarget.2025; 16(1): 481. CrossRef
Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A Meta-Analysis
Lian Hu, Jia-Wei Hu, Chang-Quan Wang, Rui-Ying Li, Song Li
Clinical Genitourinary Cancer.2025; 23(5): 102408. CrossRef
Muscle-Invasive Bladder Cancer: A Watershed Moment
Matthew D. Galsky, Leslie Ballas, Ashish M. Kamat
Journal of Clinical Oncology.2025; 43(27): 3041. CrossRef
Current Status and Future Perspectives of Immunotherapies in Bladder Cancer
Gökhan Çolak, Bilgin Demir
Acta Haematologica Oncologica Turcica.2025;[Epub] CrossRef
Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Keiichiro Miyajima, Shota Inoue, Ahmed R. Alfarhan, Abdulrahman S. Alqahtani, Markus von Deimling, Malte W. Vetterlein, Jeremy Yuen-Chun Teoh, David D’Andrea, Margit Fisch, Shahrokh F. Shariat
World Journal of Urology.2025;[Epub] CrossRef
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Shibo Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Raoshan Luo, Weiming Liang
Frontiers in Immunology.2024;[Epub] CrossRef
What’s new about the tumor microenvironment of urothelial carcinoma?
João Queirós Coelho, Maria João Ramos, Ridhi Ranchor, Rita Pichel, Laura Guerra, Hugo Miranda, Joana Simões, Sérgio Xavier Azevedo, Joana Febra, António Araújo
Clinical and Translational Oncology.2024; 26(7): 1549. CrossRef
A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues
Yi Huang, Chengxiao Liao, Zefeng Shen, Yitong Zou, Weibin Xie, Qinghua Gan, Yuhui Yao, JunJiong Zheng, Jianqiu Kong
Frontiers in Immunology.2024;[Epub] CrossRef
Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
Cheng Luo, Shuhang Luo, Wumier Wusimanjiang, Zongren Wang, Ping Liu, Bin Wang, Dan Yuan, Hao Lin, Abai Xu, Nan Deng, Kaihui Wu, Xuejin Zhu, Peng Xu, Junxing Chen, Bin Huang
Clinical and Translational Oncology.2024; 26(7): 1759. CrossRef
Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies
Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Cancer Research and Treatment.2024; 56(3): 893. CrossRef
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Thomas Powles, James W.F. Catto, Matthew D. Galsky, Hikmat Al-Ahmadie, Joshua J. Meeks, Hiroyuki Nishiyama, Toan Quang Vu, Lorenzo Antonuzzo, Pawel Wiechno, Vagif Atduev, Ariel G. Kann, Tae-Hwan Kim, Cristina Suárez, Chao-Hsiang Chang, Florian Roghmann, M
New England Journal of Medicine.2024; 391(19): 1773. CrossRef
Klassische Chemotherapie, Immuntherapie oder adjuvante Strahlentherapie – Wie können wir die onkologischen Ergebnisse der radikalen Zystektomie verbessern?
Pia Paffenholz, Stefanie Zschäbitz
Die Urologie.2024; 63(10): 994. CrossRef
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer
Jan-Jaap J. Mellema, Bas W.G. van Rhijn, Michiel S. van der Heijden
Current Opinion in Urology.2023; 33(5): 404. CrossRef

11,135 View
336 Download
30 Web of Science
31 Crossref

Sarcoma

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response: Jung Yong Hong, Hee Jin Cho, Kum-Hee Yun, Young Han Lee, Seung Hyun Kim, Wooyeol Baek, Sang Kyum Kim, Yurimi Lee, Yoon-La Choi, Minsuk Kwon, Hyo Song Kim, Jeeyun Lee; Cancer Res Treat. 2023;55(2):671-683. Published online September 27, 2022; DOI: https://doi.org/10.4143/crt.2022.251

Abstract PDF Supplementary Material PubReader ePub

Purpose
Even though pazopanib, a multitargeted tyrosine kinase inhibitor, has been approved for refractory soft tissue sarcoma (STS), little is known about the molecular determinants of the response to pazopanib. We performed integrative molecular characterization to identify potential predictors of pazopanib efficacy.
Materials and Methods
We obtained fresh pre-treatment tumor tissue from 35 patients with advanced STS receiving pazopanib-based treatment. Among those, 18 (51.4%) received pazopanib monotherapy, and the remaining 17 (48.6%) received pazopanib in combination with durvalumab, programmed death-ligand 1 blockade. Whole-exome and transcriptome sequencing were performed for each tumor and patient germline DNA.
Results
Of the 35 patients receiving pazopanib-based treatment, nine achieved a partial response (PR), resulting in an objective response rate (ORR) of 27.3%, and the median progression-free survival (PFS) was 6.0 months. Patients with CDK4 amplification (copy ratio tumor to normal > 2) exhibited shorter PFS (3.7 vs. 7.9 months, p=2.09×10–4) and a poorer response (ORR; 0% vs. 33.3%) compared to those without a gene amplification (copy ratio ≤ 2). Moreover, non-responders demonstrated transcriptional activation of CDK4 via DNA amplification, resulting in cell cycle activation. In the durvalumab combination cohort, seven of the 17 patients (41.2%) achieved a PR, and gene expression analysis revealed that durvalumab responders exhibited high immune/stromal cell infiltration, mainly comprising natural killer cells, compared to non-responders as well as increased expression of CD19, a B-cell marker.
Conclusion
Despite the limitation of heterogeneity in the study population and treatment, we identified possible molecular predictors of pazopanib efficacy that can be employed in future clinical trials aimed at evaluating therapeutic strategies.

Citations

Citations to this article as recorded by

A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas
Fernanda Picozzi, Alessandro Ottaiano, Antonella Lucia Marretta, Mariachiara Santorsola, Lucia Cannella, Antonio Pizzolorusso, Francesco Caraglia, Giuseppina Della Vittoria Scarpati, Alessandra Bracigliano, Ottavia Clemente, Ines Simeone, Michele Caraglia
Journal of Translational Medicine.2026;[Epub] CrossRef
Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study
Seda Jeral Evinç, Çağla Eyüpler Akmercan, Selin Cebeci, Zeliha Birsin, İsmail Nazlı, Ali Kaan Güren, Selver Işık, Bahadır Köylü, İlknur Deliktaş Onur, Tugay Atasever, Tuğba Kaya, Emir Çerme, Murat Günaltılı, Berrin Papila, Nebi Serkan Demirci, Çiğdem Papi
Frontiers in Oncology.2026;[Epub] CrossRef
Role of Genetics in Sarcoma for the Practicing General Surgeon
Matthew Steensma
Surgical Clinics of North America.2026; 106(4): 619. CrossRef
Musculoskeletal Diseases: Mechanisms and Therapeutic Advances
Xiao Ma, Eloy Yinwang, Xupeng Chai, Fangqian Wang, Zehao Chen, Shengdong Wang, Hao Zhou, Yucheng Xue, Jiangchu Lei, Fanglu Chen, Hengyuan Li, Shixin Chen, Shenzhi Zhao, Kelei Wang, Liang Chen, Junjie Gao, Zhaoming Ye, Nong Lin
MedComm.2025;[Epub] CrossRef
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
Hee Jin Cho, Kum-Hee Yun, Su-Jin Shin, Young Han Lee, Seung Hyun Kim, Wooyeol Baek, Yoon Dae Han, Sang Kyum Kim, Hyang Joo Ryu, Joohee Lee, Iksung Cho, Heounjeong Go, Jiwon Ko, Inkyung Jung, Min Kyung Jeon, Sun Young Rha, Hyo Song Kim
Nature Communications.2024;[Epub] CrossRef
The high-density lipoprotein binding protein HDLBP is an unusual RNA-binding protein with multiple roles in cancer and disease
Jonathan Feicht, Ralf-Peter Jansen
RNA Biology.2024; 21(1): 312. CrossRef
Intracranial Relapse in Pediatric Sarcoma
Danielle E. Smith, Tyler Hamby, Kenneth Heym, Ashraf Mohamed, Kelly L. Vallance, Anish Ray
Journal of Pediatric Hematology/Oncology.2023; 45(7): e810. CrossRef

10,138 View
242 Download
7 Web of Science
7 Crossref

Genitourinary cancer

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy: Ryul Kim, Jung Yong Hong, Jeeyun Lee, Ghee Young Kwon, Byong Chang Jeong, Se Hoon Park; Cancer Res Treat. 2022;54(3):894-906. Published online November 17, 2021; DOI: https://doi.org/10.4143/crt.2021.854

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).
Materials and Methods
We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).
Results
We identified frequent molecular dysregulations in chromatin regulatory genes (KDM6A, ARID1A, MLL2, and STAG2) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1–positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1–negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1–positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1–positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.
Conclusion
Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.

Citations

Citations to this article as recorded by

Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines
Mohammad Mahdi Ajalli, Yalda Sansebli, Davood Ekrami, Fatemeh Alaeenejad, Ainaz Abbasi, Pooya Eini, Farnaz Hassanzadeh, Nastaran Bahrami
Clinical and Experimental Medicine.2026;[Epub] CrossRef
Perspective on the integration of radiomics and spatial omics in the analysis of the tumor microenvironment of bladder cancer and prospects for precision diagnosis and treatment
Yan Dong, Yunwei Su
Frontiers in Immunology.2026;[Epub] CrossRef
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Areti Strati, Christos Adamopoulos, Ioannis Kotsantis, Amanda Psyrri, Evi Lianidou, Athanasios G. Papavassiliou
International Journal of Molecular Sciences.2025; 26(3): 1235. CrossRef
Development of a Technique for Diagnosis and Screening of Superficial Bladder Cancer by Cell-Pellet DNA From Urine Sample
Jaekwon Seok, Hee Jeong Kwak, Chan-Koo Kang, Ah Ram Kim, Woo Suk Choi, Hyoung Keun Park, Sung Hyun Paick, Hyeong Gon Kim, Yeonjoo Kwak, Tak-Il Jeon, Kyung Min Lim, Baeckseung Lee, Aram Kim, Ssang-Goo Cho
Laboratory Investigation.2025; 105(6): 104124. CrossRef
Sex-Specific Associations of Glycemic Status and Smoking with Bladder Cancer Risk: A Nationwide Cohort Study
Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen
Cancers.2025; 17(13): 2262. CrossRef
The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy
Li-Juan Chen, Xin-Yang Xu, Xiao-Dan Zhong, Yan-Jun Liu, Ming-Hui Zhu, Fan Tao, Chang-Yun Li, Qiu-Sheng She, Guan-Jun Yang, Jiong Chen
Bioorganic Chemistry.2023; 133: 106409. CrossRef
A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
Zheng Zhou, Yusong Zhou, Wei Liu, Jing Dai
Frontiers in Genetics.2023;[Epub] CrossRef
Implication of KDM6A in Bladder Cancer
Marianne Matar, Gilles Prince, Ibrahim Hamati, Maria Baalbaky, Jonas Fares, Marc Aoude, Charbel Matar, Hampig Raphael Kourie
Pharmacogenomics.2023; 24(9): 509. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park
Biomedicines.2022; 10(8): 2005. CrossRef
Antineoplastics

Reactions Weekly.2022; 1933(1): 61. CrossRef
Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma
Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
Frontiers in Pharmacology.2022;[Epub] CrossRef

10,956 View
260 Download
10 Web of Science
11 Crossref

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial: Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim; Cancer Res Treat. 2020;52(2):374-387. Published online August 13, 2019; DOI: https://doi.org/10.4143/crt.2019.198

Abstract PDF PubReader ePub

Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by

Epstein-Barr virus-associated tumors: commonalities in pathogenesis and the tumor immune microenvironment
Xiyi Wang, Dongmei Hu, Renqin Li, Wenjun Liao, Chao Li, Qiuhan Liu, Jiayao Li, Qiaohua Li, Wenpei Guo, Liyang Wang, Shichuan Zhang, Yue Zhao
Frontiers in Immunology.2026;[Epub] CrossRef
Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies
Qihao Zhang, Xin Wang
Cancers.2026; 18(9): 1358. CrossRef
Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review
Anna Aureli, Giulia Lanzilli, Stefano Vito Boccadamo Pompili, Giulio Cesare Spagnoli, Giuseppe Sconocchia, Sara Caratelli
Frontiers in Immunology.2026;[Epub] CrossRef
Viral oncogenesis in cancer: from mechanisms to therapeutics
Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
CD30 associates with EBER-EBV but not HCV-NS3 in T-cell non-Hodgkin lymphoma
Rizki Amalia Juwita, Lili Ananta Saputra, Ika Fiilasari, Mardiah Suci Hardianti, Nungki Anggorowati
Frontiers in Virology.2025;[Epub] CrossRef
Unusual lymphomas: Unusual sites
Ajay Joseph Kaveripakam, Meetu Agrawal, Kaushal Kalra, Sana Ahuja, Neha Kawatra Madan
Journal of Hematology and Allied Sciences.2025; 5: 149. CrossRef
Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation
Yunfei Shi, Xianghong Li
Pathology - Research and Practice.2025; 272: 156098. CrossRef
Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients
Cansu Barış Moğul, Sibel Hacıoğlu, Nilay Şen Türk, Vildan Caner, Hande Şenol
Journal of Basic and Clinical Health Sciences.2025; 9(3): 593. CrossRef
Development of a Radiomic-clinical Nomogram for Prediction of Survival in Patients with Nasal Extranodal Natural Killer/T-cell Lymphoma
Limin Chen, Zhao Wang, Xiaojie Fang, Mingjie Yu, Haimei Ye, Lujun Han, Ying Tian, Chengcheng Guo, Huang He
Current Medical Imaging Formerly Current Medical Imaging Reviews.2025;[Epub] CrossRef
A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
Masahito Tokunaga, Junya Makiyama, Motoaki Shiratsuchi, Takanori Toyama, Satoshi Oka, Ilseung Choi, Takahiro Yoshida, Kiyoshi Okazuka, Atae Utsunomiya
Hematological Oncology.2025;[Epub] CrossRef
Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma
Qisi Lu, Tao You, Qian Cheng, Zhe-Sheng Chen, Haiwen Huang
Drug Discovery Today.2025; 30(12): 104549. CrossRef
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study
Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant, Maya Hacini, Kamel Laribi, Sébastien Bailly, Thibaut Belmondo, Marie Maerevoet, Loic Ysebaert, Stéphanie Guidez, Steven Le Gouill, Christophe Bonnet, Marc André, Jehan Dupuis, Catherine Thieblemont,
Blood Advances.2025; 9(24): 6292. CrossRef
Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
Current Cancer Therapy Reviews.2024; 20(1): 53. CrossRef
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
The Journal of Dermatology.2024; 51(8): 1037. CrossRef
Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
Journal of International Medical Research.2024;[Epub] CrossRef
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
British Journal of Clinical Pharmacology.2024; 90(10): 2571. CrossRef
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
Chengji Wang, Liang Wang
Chinese Medical Journal.2024; 137(19): 2308. CrossRef
Research progress on EBV-associated NK/T cell lymphoma
Jun CAI, Yi CAO, LiYun QIU, Yan GAO, HuiQiang HUANG, QingQing CAI
SCIENTIA SINICA Vitae.2024; 54(12): 2363. CrossRef
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
Frontiers in Immunology.2023;[Epub] CrossRef
Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Cancers.2023; 15(5): 1366. CrossRef
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
Advances in Radiation Oncology.2023; 8(6): 101279. CrossRef
Novel target and treatment agents for natural killer/T-cell lymphoma
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
Journal of Hematology & Oncology.2023;[Epub] CrossRef
Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
Cancer Innovation.2023; 2(5): 346. CrossRef
Advances and challenges of immunotherapies in NK/T cell lymphomas
Ling He, Na Chen, Lei Dai, Xingchen Peng
iScience.2023; 26(11): 108192. CrossRef
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
Cancer Medicine.2023; 12(24): 21725. CrossRef
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
Blood Research.2023; 58(4): 194. CrossRef
Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
Diagnostics.2022; 12(2): 409. CrossRef
Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
Blood.2022; 139(13): 1999. CrossRef
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
Cancers.2022; 14(8): 1917. CrossRef
Basic immunohistochemistry for lymphoma diagnosis
Junhun Cho
Blood Research.2022; 57(S1): S55. CrossRef
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
Journal of Clinical Medicine.2022; 11(10): 2699. CrossRef
CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
Diagnostic Pathology.2022;[Epub] CrossRef
EBV-associated NK and T-cell lymphoid neoplasms
Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
Current Opinion in Oncology.2022; 34(5): 422. CrossRef
Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
Cancers.2022; 14(21): 5458. CrossRef
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
Seminars in Hematology.2022; 59(4): 198. CrossRef
Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
Frontiers in Oncology.2021;[Epub] CrossRef
NK-/T-cell lymphomas
Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
Leukemia.2021; 35(9): 2460. CrossRef
The landscape of new drugs in extranodal NK/T-cell lymphoma
Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
Cancer Treatment Reviews.2020; 89: 102065. CrossRef
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
Experimental Hematology & Oncology.2020;[Epub] CrossRef
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Lin-rong Li, Ken H. Young
Journal of Hematology & Oncology.2020;[Epub] CrossRef
A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
SSRN Electronic Journal .2020;[Epub] CrossRef

14,557 View
647 Download
39 Web of Science
41 Crossref

Case Report

TTP-HUS Associated with Sunitinib: Moon Ki Choi, Jung Yong Hong, Jun Ho Jang, Ho Yeong Lim; Cancer Res Treat. 2008;40(4):211-213. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.211

Abstract PDF PubReader ePub

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare condition that is severe and may be fatal. Adverse reactions to drugs increasingly are reported as probable causes of TTP-HUS. Many chemotherapeutic agents have also been implicated in causing TTP-HUS. We reported a woman with metastatic renal cell carcinoma who presented with TTP-HUS associated with sunitinib. She had gross hematuria and generalized edema. The hemoglobin concentration was 8.9 g/dl and the platelet count was 46,000/mm³. Her reticulocyte count was increased to 4.1% and the peripheral blood smear revealed red blood cell fragmentation and spherocytes. The patient completely recovered after discontinuing the use of sunitinib and undergoing plasmapheresis. Because of the increasing use of sunitinib in the treatment of cancer patients, oncologists should be aware of the possibility of TTP-HUS related to sunitinib, as early recognition and prompt therapeutic intervention can be beneficial.

Citations

Citations to this article as recorded by

Chemotherapy and hemostasis disorders
E. V. Slukhanchuk, V. O. Bitsadze, A. G. Solopova, J. Kh. Khizroeva, K. N. Grigoreva, N. R. Gashimova, N. A. Makatsariya, D. V. Blinov, V. N. Galkin, A. Yu. Shatilina, E. M. Lyadnova, N. A. Shulga, L. T. Toguzaeva, S. Morkos, J.-C. Gris, I. Elalamy, G. Ge
Obstetrics, Gynecology and Reproduction.2025; 18(6): 835. CrossRef
Atypical hemolytic uremic syndrome
Patrick R. Walsh, David Kavanagh
Journal of Allergy and Clinical Immunology.2025; 156(2): 224. CrossRef
Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy
Anukul Ghimire, Rebecca Brassington, Kim Solez, Aminu Bello
BMJ Case Reports.2024; 17(1): e255841. CrossRef
Nonthrombocytopenic, noninflammatory simplex purpura during sunitinib therapy
Marta García‐Legaz Martínez, Álvaro Martínez‐Doménech, Gemma Pérez‐Pastor, Jorge Magdaleno‐Tapial, Cristian Valenzuela‐Oñate, Víctor Alegre‐de Miquel, Amparo Pérez‐Ferriols
International Journal of Dermatology.2019;[Epub] CrossRef
Thrombotic microangiopathy in cancer patients
Alexander D. Makatsariya, Ismail Elalamy, Alexander V. Vorobev, Angelina S. Bakhtina, Muyang Meng, Victoria O. Bitsadze, Jamilya Kh. Khizroeva
Annals of the Russian academy of medical sciences.2019; 74(5): 323. CrossRef
Thrombotic microangiopathy in cancer
Ilene Ceil Weitz
Thrombosis Research.2018; 164: S103. CrossRef
Cancer drugs and the glomerulus
Hitesh H Shah, Nupur N Uppal, Mark A Perazella
Journal of Onco-Nephrology.2018; 2(2-3): 78. CrossRef
Therapeutic Plasma Exchange and Its Impact on Drug Levels
Caleb W Cheng, Jeanne E Hendrickson, Christopher A Tormey, Davinder Sidhu
American Journal of Clinical Pathology.2017; 148(3): 190. CrossRef
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Hassan Izzedine, Mark A. Perazella
American Journal of Kidney Diseases.2015; 66(5): 857. CrossRef
Sunitinib-associated Thrombotic Microangiopathy: A Significant Risk
F.D. Buckley, G. Preston, D.J. Meiklejohn, D. Adamson
Clinical Oncology.2014; 26(8): 515. CrossRef
Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature
Rebecca L. Ruebner, Lawrence Copelovitch, Nicholas F. Evageliou, Michelle R. Denburg, Jean B. Belasco, Bernard S. Kaplan
Pediatric Nephrology.2014; 29(5): 863. CrossRef
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma
Liliane Hobeika, Sally E Self, Juan Carlos Q Velez
BMC Nephrology.2014;[Epub] CrossRef
Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature
Imane El Dika, Deborah Mukherji, Sally Temraz, Rita Assi, Ali Shamseddine
Case Reports in Medicine.2014; 2014: 1. CrossRef
Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor
Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Nilgün Kaya
Journal of Oncology Pharmacy Practice.2014; 20(4): 298. CrossRef
A Case of Sunitinib-Associated Thrombotic Thrombocytopenic Purpura
Eun Jin Kim, Yun Mi Choi, Sin Won Lee, Yeon Jung Ha, Jae Lyun Lee
Korean Journal of Medicine.2013; 84(2): 303. CrossRef
Thrombotic Microangiopathy Associated with Bortezomib Treatment in a Patient with Relapsed Multiple Myeloma
Urpu Salmenniemi, Kari Remes
Hematology Reports.2012; 4(2): e13. CrossRef
Hematologic toxicities of small molecule tyrosine kinase inhibitors
Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari
Targeted Oncology.2011; 6(4): 203. CrossRef
Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
H. Izzedine, C. Massard, J. C. Soria
Clinical Kidney Journal.2011; 4(1): 78. CrossRef
Docetaxel-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome–Related Complex in a Patient With Metastatic Prostate Cancer?
Anuj Shrestha, Pam Khosla, Yunfei Wei
American Journal of Therapeutics.2011; 18(5): e167. CrossRef
Micafungin-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Review of the Literature
Maisa Nazzal, Fadi Safi, Freda Arma, Mustafa Nazzal, Mahvish Muzaffar, Ragheb Assaly
American Journal of Therapeutics.2011; 18(6): e258. CrossRef
Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2009; 41(2): 67. CrossRef

12,495 View
66 Download
21 Crossref

First
Prev
Page of 1
Next
Last

Search